|
25 Companies |
|
28 Products |
|
28 Products |
|
44 Mechanisms of Action |
|
0 Trials |
|
80 News |
|
| 12» |
- | cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Apr 20, 2018
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- | Istodax (romidepsin) / Astellas, BMS
Trial completion, Trial initiation date, Trial primary completion date, Metastases: Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 14, 2017
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
- yttrium Y 90 tabituximab barzuxetan (OTSA101-DTPA-90Y) / OncoTherapy
Trial termination, Trial primary completion date: SYNFRIZZ: First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (clinicaltrials.gov) - May 17, 2017
P1, N=20, Terminated, Sponsor: Centre Leon Berard
Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008 Active, not recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Feb 2015; Too slow accrual.
- decitabine / Generic mfg.
Trial completion: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Oct 6, 2016
P1, N=19, Completed, Sponsor: University of Louisville
Active, not recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Feb 2015; Too slow accrual. Active, not recruiting --> Completed
- | Trial completion, Surgery: Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis (clinicaltrials.gov) - Jul 4, 2016
P3, N=370, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||| Trial completion, Trial initiation date, Trial primary completion date: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - May 19, 2016
P=N/A, N=70, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed Recruiting --> Completed | Initiation date: Mar 2012 --> May 2016 | Trial primary completion date: Jan 2100 --> May 2016
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 19, 2016
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Initiation date: Mar 2012 --> May 2016 | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion, Metastases: Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma (clinicaltrials.gov) - Feb 27, 2016
P2, N=40, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Completed
- decitabine / Generic mfg.
Enrollment closed, Enrollment change: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Feb 10, 2016
P1, N=19, Active, not recruiting, Sponsor: University of Louisville
Not yet recruiting --> Completed Recruiting --> Active, not recruiting | N=15 --> 19
- cyclophosphamide / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (clinicaltrials.gov) - Feb 3, 2016
P1, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | N=15 --> 19 N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Jan 2016
- Trial completion, Enrollment change: Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=20, Completed, Sponsor: St. Jude Children's Research Hospital
N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Jan 2016 Active, not recruiting --> Completed | N=50 --> 20
- Enrollment closed, Trial primary completion date: Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | N=50 --> 20 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015
- decitabine / Generic mfg.
Trial primary completion date: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Aug 19, 2015
P1, N=15, Recruiting, Sponsor: University of Louisville
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- yttrium Y 90 tabituximab barzuxetan (OTSA101-DTPA-90Y) / OncoTherapy
Enrollment closed: SYNFRIZZ: First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (clinicaltrials.gov) - Aug 14, 2015
P1, N=20, Active, not recruiting, Sponsor: Centre Leon Berard
Trial primary completion date: Aug 2015 --> Aug 2016 Suspended --> Active, not recruiting
- yttrium Y 90 tabituximab barzuxetan (OTSA101-DTPA-90Y) / OncoTherapy
Trial suspension, Trial primary completion date: SYNFRIZZ: First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (clinicaltrials.gov) - Aug 13, 2015
P1, N=20, Suspended, Sponsor: Centre Leon Berard
Suspended --> Active, not recruiting Recruiting --> Suspended | Trial primary completion date: Dec 2014 --> Jun 2015
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - May 26, 2015
P1b, N=78, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended | Trial primary completion date: Dec 2014 --> Jun 2015 Active, not recruiting --> Completed | N=120 --> 78
- ||| Enrollment open, Trial primary completion date: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - May 8, 2015
P=N/A, N=70, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=120 --> 78 Active, not recruiting --> Recruiting | Trial primary completion date: May 2012 --> Jan 2100
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 7, 2015
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting | Trial primary completion date: May 2012 --> Jan 2100 N=50 --> 30
- imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood (clinicaltrials.gov) - Apr 15, 2015
P2, N=100, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 30 Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial completion, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 12, 2014
P1, N=6, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- decitabine / Generic mfg.
Trial primary completion date: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Dec 5, 2014
P1, N=15, Recruiting, Sponsor: University of Louisville
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Aug 2015
- cyclophosphamide / Generic mfg.
Trial primary completion date, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 23, 2014
P1, N=7, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Dec 2014 --> Sep 2013
- cyclophosphamide / Generic mfg.
Enrollment closed, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 12, 2014
P1, N=7, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2014 --> Sep 2013 Recruiting --> Active, not recruiting
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Nov 7, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Apr 2015
- | Neulasta (pegfilgrastim) / Roche
Trial completion, Metastases: Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 27, 2014
P3, N=455, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Nov 2014 --> Apr 2015 Active, not recruiting --> Completed
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment closed, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 10, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P2b, N=133, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting N=370 --> 133
- | Granocyte (lenograstim) / Roche
Trial completion, Surgery: EORTC-STBSG 62931: Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P3, N=350, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=370 --> 133 Active, not recruiting --> Completed
- ||| Trial completion: Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=294, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (clinicaltrials.gov) - Jul 30, 2014
P1, N=12, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jul 2014 | Trial primary completion date: Jan 2016 --> Jun 2016
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 21, 2014
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jul 2014 | Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Aug 2014 --> Nov 2014
- cyclophosphamide / Generic mfg.
Trial primary completion date, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 26, 2014
P1, N=7, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Dec 2013 --> Dec 2014
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> Dec 2014 N=92 --> 30
- imatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Combination therapy, Metastases: Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 31, 2014
P1/2, N=14, Completed, Sponsor: National Cancer Institute (NCI)
N=92 --> 30 N=33 --> 14
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P2, N=114, Completed, Sponsor: National Cancer Institute (NCI)
N=33 --> 14 N=160 --> 114
- imatinib / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy, Metastases: Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 31, 2014
P1/2, N=14, Completed, Sponsor: National Cancer Institute (NCI)
N=160 --> 114 Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Trial completion: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P2, N=114, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 18, 2014
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=30 --> 50
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Dana-Farber Cancer Institute
N=30 --> 50 Active, not recruiting --> Completed
- Trial completion, Metastases: Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Completed Suspended --> Completed
- | imatinib / Generic mfg.
Trial completion, Metastases: Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed No longer recruiting --> Completed
- cyclophosphamide / Generic mfg.
New P1 trial, Metastases: NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (clinicaltrials.gov) - Feb 9, 2014
P1, N=12, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Trial termination: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
No longer recruiting --> Completed Active, not recruiting --> Terminated; The study was terminated due to slow accrual.
- Enrollment change: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
Active, not recruiting --> Terminated; The study was terminated due to slow accrual. N=178 --> 22
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jan 5, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=178 --> 22 Suspended --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Surgery: Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 25, 2013
P3, N=400, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sorafenib / Generic mfg.
Enrollment change, Metastases: Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma (clinicaltrials.gov) - Nov 18, 2013
P2, N=147, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=222 --> 147
- | dacarbazine / Generic mfg., sorafenib / Generic mfg.
Trial completion: Sorafenib and Dacarbazine in Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 12, 2013
P2, N=37, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=222 --> 147 Active, not recruiting --> Completed
- BI2536 / Boehringer Ingelheim
Trial completion, Metastases: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 3, 2013
P2, N=76, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed